Glycobiology Advance Access originally published online on September 29, 2006
Glycobiology 2007 17(1):104-118; doi:10.1093/glycob/cwl057
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types
Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd, 3-6-6 Asahi-machi, Machida-shi, Tokyo 194-8533, Japan
1 To whom correspondence should be addressed; Tel: +81 42-725-2556; Fax: +81 42-726-8330; e-mail: msatoh{at}kyowa.co.jp
Received on August 23, 2006; revised on September 25, 2006; accepted on September 25, 2006
The structure of asparagine-linked oligosaccharides attached to the antibody constant region (Fc) of human immunoglobulin G1 (IgG1) has been shown to affect the pharmacokinetics and antibody effector functions of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). However, it is still unclear how differences in the N-linked oligosaccharide structures impact the biological activities of antibodies, especially those lacking core fucose. Here, we succeeded in generating core fucose-lacking human IgG1 antibodies with three different N-linked Fc oligosaccharides, namely, a high-mannose, hybrid, and complex type, using the same producing clone, and compared their activities. Cultivation of an 
-1,6-fucosyltransferase (FUT8) knockout Chinese hamster ovary cell line in the presence or absence of a glycosidase inhibitor (either swainsonine or kifunensine) yielded antibody production of each of the three types without contamination by the others. Two of three types of nonnaturally occurring atypical oligosaccharide IgG1, except the complex type, reduced the affinity for both human lymphocyte receptor IIIa (Fc
RIIIa) and the C1q component of the complement, resulting in reduction of ADCC and CDC. The bulky structure of the nonreducing end of N-linked Fc oligosaccharides is considered to contribute the CDC change, whereas the structural change in the reducing end, i.e. the removal of core fucose, causes ADCC enhancement through improved FcRIIIa binding. In the pharmacokinetic profile, although no significant difference of human neonatal Fc receptor (FcRn)-binding affinity was observed among the three types, the complex type showed longer serum half-lives than the other types irrespective of core fucosylation in mice, which also suggests the contribution of the nonreducing end structure. The present study provides basic information on the effects of core fucose-lacking N-linked Fc oligosaccharides on antibody biological activities.
Key words: antibody effector functions / Fc oligosaccharides / IgG1 lacking core-fucosylation / N-linked oligosaccharide structure / pharmacokinetics
None declared.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  X. Chen, Y D. Liu, and G. C Flynn The effect of Fc glycan forms on human IgG2 antibody clearance in humans Glycobiology, March 1, 2009; 19(3): 240 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Dimitrov, J. Bayry, S. Siberil, and S. V. Kaveri Sialylated therapeutic IgG: a sweet remedy for inflammatory diseases? Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1301 - 1304. [Full Text] [PDF]
|
|